UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline

Journal of clinical oncology, 2022-04, Vol.40 (12), p.1356-1384

2022

Volltextzugriff (PDF)

Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma

Journal of clinical oncology, 2018-10, Vol.36 (28), p.2863-2871

2018

Volltextzugriff (PDF)

Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer

Cancer discovery, 2016-12, Vol.6 (12), p.1334-1341

2016

Volltextzugriff (PDF)

Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies

Cancers, 2021-06, Vol.13 (13), p.3164

2021

Volltextzugriff (PDF)

Feasibility of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Cytology Specimens for Next Generation Sequencing in Non–small-cell Lung Cancer

Clinical lung cancer, 2018-05, Vol.19 (3), p.230-238.e2

2018

Volltextzugriff (PDF)

Phase II Study of Pemetrexed and Carboplatin Plus Bevacizumab With Maintenance Pemetrexed and Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2009-07, Vol.27 (20), p.3284-3289

2009

Volltextzugriff (PDF)

Lung Cancer in Women

Journal of clinical oncology, 2005-05, Vol.23 (14), p.3212-3218

Patel, Jyoti D

2005

Volltextzugriff (PDF)

Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors

Frontiers in oncology, 2020-10, Vol.10, p.576314-576314

2020

Volltextzugriff (PDF)

Regulation of VEGFR2 and AKT Signaling by Musashi-2 in Lung Cancer

Cancers, 2023-04, Vol.15 (9), p.2529

2023

Volltextzugriff (PDF)

Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma, Bronchioloalveolar Carcinoma Subtype, Predict Response to Erlotinib

Journal of clinical oncology, 2008-03, Vol.26 (9), p.1472-1478

2008

Volltextzugriff (PDF)

Addition of Trastuzumab Deruxtecan to Selpercatinib in a Patient With RET Fusion-Driven NSCLC and an Acquired HER2 Amplification: Case Report

JTO clinical and research reports, 2023-12, Vol.4 (12), p.100603, Article 100603

2023

Volltextzugriff (PDF)

Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

Journal of clinical oncology, 2014-01, Vol.32 (2), p.129-160

2014

Volltextzugriff (PDF)

Chemotherapy and Targeted Therapeutics as Maintenance of Response in Advanced Non-Small Cell Lung Cancer

Seminars in oncology, 2014-02, Vol.41 (1), p.93-100

2014

Volltextzugriff (PDF)

The Prognostic and Therapeutic Potential of DNA Damage Repair Pathway Alterations and Homologous Recombination Deficiency in Lung Cancer

Cancers, 2022-10, Vol.14 (21), p.5305

2022

Volltextzugriff (PDF)

Clinical Cancer Advances 2011: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

Journal of clinical oncology, 2012-01, Vol.30 (1), p.88-109

2012

Volltextzugriff (PDF)

Current and Emerging Treatment Options for Patients with Metastatic EGFR-Mutated Non-small Cell Lung Cancer After Progression on Osimertinib and Platinum-Based Chemotherapy: A Podcast Discussion

Advances in therapy, 2023-12, Vol.40 (12), p.5579-5590

2023

Volltextzugriff (PDF)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma

Journal for immunotherapy of cancer, 2022-05, Vol.10 (5), p.e003956

2022

Volltextzugriff (PDF)

Early stage lung cancer detection in systemic sclerosis does not portend survival benefit: a cross sectional study

PloS one, 2015-02, Vol.10 (2), p.e0117829-e0117829

2015

Volltextzugriff (PDF)

Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors

Journal of clinical oncology, 2018-06, Vol.36 (16), p.1611-1618

2018

Volltextzugriff (PDF)

Patterns and Predictors of Chemotherapy Use for Resected Non-Small Cell Lung Cancer

The Annals of thoracic surgery, 2016-02, Vol.101 (2), p.533-540

2016

Volltextzugriff (PDF)

Top advances in lung cancer, 2021

Cancer, 2022-10, Vol.128 (19), p.3434-3437

2022

Volltextzugriff (PDF)

Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A

Journal of clinical oncology, 2022-07, Vol.40 (21), p.2295-2307

2022

Volltextzugriff (PDF)

Dynamic Changes in Circulating Tumor Fraction as a Predictor of Real-World Clinical Outcomes in Solid Tumor Malignancy Patients Treated with Immunotherapy

Oncology and therapy, 2024-09, Vol.12 (3), p.509-524

2024

Volltextzugriff (PDF)

1 – 25 von 281

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(256)
Mit Volltextzugriff
(238)

Publikationsform

Sprache

Englisch
(281)
Japanisch
(21)

Erscheinungsjahr

n.n

Thema

Science & Technology
(156)
Life Sciences & Biomedicine
(148)
Humans
(113)
Oncology
(100)
Male
(58)
Female
(55)
Lung Neoplasms - Drug Therapy
(46)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(39)
Middle Aged
(36)
Aged
(33)
Lung Neoplasms - Pathology
(32)
Biological And Medical Sciences
(30)
Adult
(29)
Lung Cancer
(28)
Medical Sciences
(28)
Treatment Outcome
(24)
Tumors
(24)
Carcinoma, Non-Small-Cell Lung - Pathology
(22)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(21)
Animals
(20)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline

Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma

PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer

Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer

Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies

Feasibility of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Cytology Specimens for Next Generation Sequencing in Non–small-cell Lung Cancer

Phase II Study of Pemetrexed and Carboplatin Plus Bevacizumab With Maintenance Pemetrexed and Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer

Lung Cancer in Women

Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors

Regulation of VEGFR2 and AKT Signaling by Musashi-2 in Lung Cancer

Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma, Bronchioloalveolar Carcinoma Subtype, Predict Response to Erlotinib

Addition of Trastuzumab Deruxtecan to Selpercatinib in a Patient With RET Fusion-Driven NSCLC and an Acquired HER2 Amplification: Case Report

Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

Chemotherapy and Targeted Therapeutics as Maintenance of Response in Advanced Non-Small Cell Lung Cancer

The Prognostic and Therapeutic Potential of DNA Damage Repair Pathway Alterations and Homologous Recombination Deficiency in Lung Cancer

Clinical Cancer Advances 2011: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

Current and Emerging Treatment Options for Patients with Metastatic EGFR-Mutated Non-small Cell Lung Cancer After Progression on Osimertinib and Platinum-Based Chemotherapy: A Podcast Discussion

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma

Early stage lung cancer detection in systemic sclerosis does not portend survival benefit: a cross sectional study

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors

Patterns and Predictors of Chemotherapy Use for Resected Non-Small Cell Lung Cancer

Top advances in lung cancer, 2021

Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A

Dynamic Changes in Circulating Tumor Fraction as a Predictor of Real-World Clinical Outcomes in Solid Tumor Malignancy Patients Treated with Immunotherapy

Suchergebnisse filtern